OTC - BIOTECH mit KGV von unter 10 - 500 Beiträge pro Seite

[Inkmarker]

Der Wert um den es geht, ist Synbiotics. Zum KGV verweise ich auf die Meldung vom 28.05.2004.

Hier ist sie nochmal:


Synbiotics Corporation Reports Year-End and First Quarter Results
SAN DIEGO

Synbiotics Corporation, San Diego
858-451-3771
Paul R. Hays, President & COO, x1401
[e-mail]
or
Keith A. Butler, Vice President and CFO, x1413
[e-mail]

Synbiotics Corporation (OTCBB: SBIO) today announced record earnings for the year ended December 31, 2003. Net income for the year was a record $1,287,000 or $0.06 per share ($0.03 on a diluted basis) compared to a net loss of ($14,401,000) or ($1.00) per share for 2002. The company also announced today that it recorded a net loss for the first quarter of 2004 of ($495,000) or ($0.03) per share compared to net income of $1,389,000 or $0.07 per share ($0.03 on a diluted basis) for the prior year period.

The 2003 results include a one-time litigation settlement gain of $515,000 or $0.03 per share ($0.01 per share on a diluted basis), whereas 2002 was negatively impacted by one-time charges related to retention bonuses and goodwill impairment totaling $14,315,000 or $0.98 per share. The results for the first quarter of 2004 include significant legal expenses.

Synbiotics` revenues were $19,211,000 for 2003, a decrease of 11% from $21,671,000 for 2002. Revenues for the first quarter of 2004 were $5,178,000, a decrease of 16% from $6,150,000 for the prior year period. The decrease in both periods is primarily due to the April 2003 termination by Agen Biomedical Ltd. of our contract manufacturing agreement for certain of our Witness(R) in clinic diagnostic tests, and Agen`s entry into the US canine heartworm diagnostic market in October 2003 with, we believe, a product which infringes our heartworm patent.

Paul Hays, Synbiotics` President and Chief Operating Officer, said, "We are very pleased with our year-end results considering we were without our key Witness(R) products for nine months. The restructuring implemented in 2002 together with continued cost containment allowed us to produce these record results. While we have re-introduced our Witness(R) HW canine heartworm test in January 2004, we have also had to defend our market share and price erosion attributed to the US entry of Agen, our former contract manufacturer of Witness(R) products, with a product similar to our Witness(R) product. Synbiotics contends that Agen`s product infringes our US patent. Litigation costs associated with defending our patent rights have negatively affected the first quarter 2004 earnings. We have confidence that we will prevail in the trial scheduled to begin June 28, 2004. Win or lose, once the suit is behind us, we are positioned, with our recently realigned global sales forces to grow our revenue through greater market penetration with current products and through the introduction of new products from our development activities."

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company`s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including uncertainty of litigation outcomes, competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the ability to assimilate acquired businesses, the continued effect on the business from our 2002 lack of liquidity, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.




Es fragt sich natürlich, warum der Kurs so im Ar... ist. Ein wesentlicher Grund dürfte sein, dass die Aktie derzeit bei den Pk notiert ist, da die Quartalszahlen zu spät eingereicht wurden. Ferner dürften aber auch Patentstreitigkeiten dafür verantwortlich sein. Letztere wurden aber zwischenzeitlich zum Teil beigelegt, wobei ich auf folgende Meldung verweise:


Synbiotics Corporation Secures Settlement with Agen
SAN DIEGO

Synbiotics Corporation
Paul R. Hays, President & COO
858-451-3771, ext. 1401
[e-mail]
or
Keith A. Butler, Vice President and CFO
858-451-3771, ext. 1413
[e-mail]

Synbiotics Corporation (OTCBB:SBIO) today announced that it has entered into a settlement with Agen Biomedical Ltd. resolving all ongoing litigation regarding Synbiotics` U.S. heartworm patent and other contractual matters. The litigation, which began in September 2003, concerned alleged infringement of Synbiotics` United States Patent 4,789,631 for canine heartworm diagnostics and related supply contract issues.

Neither party admitted any liability and both will make application to the respective courts to have their respective cases dismissed with prejudice. "This has been a costly and distracting process. Although Synbiotics` confidence in its position and commitment to protecting patents has never wavered, this settlement is in the best interest of all parties," said Paul R. Hays, President of Synbiotics Corporation.

This is the third patent infringement suit by Synbiotics to enforce its `631 patent, which covers its canine heartworm kits. "We felt that it was important to enforce this patent because it covers the antibody which has become the gold standard in heartworm diagnosis," said Hays.

Under the agreement Synbiotics granted Agen a license to the U.S. heartworm patent in exchange for a license fee to be paid now and in June 2005. Further, Agen granted Synbiotics a license under Agen`s European FIV patent and Synbiotics granted Agen a license to use a Japanese trademark.

In addition, Synbiotics will supply certain antibodies to Agen for use in the manufacture of specific test kits. Agen will pay Synbiotics a transfer price for the antibodies and a percentage of sales for those test kits.

"We are pleased with the terms of this settlement and believe it is in the best interest of our customers, shareholders and employees. It enables Synbiotics to return its focus to growing our business according to our plan," said Hays.

Agen formerly contract manufactured and supplied to Synbiotics some Witness(R) brand test kits containing Synbiotics antibodies under a For Further Manufacture USDA license. Agen terminated that supply agreement in April 2003 and Synbiotics has since obtained a new contract supplier for those Witness(R) brand test kits.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics and related products for the veterinary practice, veterinary laboratory and livestock & poultry markets worldwide. Headquartered in San Diego, Synbiotics develops, manufactures and distributes its products through its operations in San Diego and Lyon, France. For information on Synbiotics and its products, visit the Company`s Web site at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the Company`s overdue bank debt, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.


Am heutigen Tag wurde nun die Zusammenarbeit mit ABAXIS verkündert, worauf die Aktie bisher leicht zulegte.

Hier die aktuellen NEWS:


Synbiotics Corp. Announces Co-Promotion Agreement with Abaxis
SAN DIEGO

Synbiotics Corp.
Kent Luther, Vice President, Sales & Marketing
858-451-3771, ext. 1102
[e-mail]
or
Paul R. Hays, President & COO
858-451-3771, ext. 1401
[e-mail]

Synbiotics Corp. (Pink Sheets:SBIO) announced today that it has entered into a Co-Promotion Agreement with Abaxis Inc. (Nasdaq:ABAX). The two companies are offering incentives to veterinary clinics currently utilizing both the Witness(R) HW canine heartworm antigen test and the VetScan(R) in-clinic chemistry analyzer, as well as any new customers that purchase both products during the co-promotional period. The co-promotion begins on July 12, 2004, and will be available to all qualified veterinary practices in the United States.

"Synbiotics is pleased to be part of such a strong promotion that rewards current and future loyal customers of both Witness(R) HW and VetScan(R)," said Kent Luther, Vice President of Sales and Marketing at Synbiotics. "This agreement will increase the awareness and market share of Witness(R) HW through the promotion by Abaxis` direct sales force and strong distributor alliances."

"We are enthusiastic about the alliance between the VetScan(R) and Witness(R) HW product lines and believe this co-promotion will solidify customer loyalty for both companies," stated Richard Schoen, Vice President of Sales and Marketing at Abaxis. "We are proud to be partnering with a company who manufactures a complementary product with quality and value comparable to the VetScan(R)."

Synbiotics Corp. develops, manufactures and markets veterinary diagnostics and related products for the veterinary practice, veterinary laboratory and livestock & poultry markets worldwide. Headquartered in San Diego, Synbiotics develops, manufactures and distributes its products through its operations in San Diego and Lyon, France. For information on Synbiotics and its products, visit the Company`s Web site at www.synbiotics.com.

Abaxis Inc. develops, manufactures and markets portable blood analysis systems for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9 kilogram, portable analyzer and a series of 8-cm diameter single-use plastic disks, called rotors or reagent discs, that contain all the reagents necessary to perform a fixed menu of tests. The system can be operated with minimal training and perform multiple tests on whole blood using either venous or fingerstick samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory. For information on Abaxis and its products, visit the Company`s Web site at www.abaxis.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, Synbiotics Corp.`s overdue bank debt, the seasonality of major portions of Synbiotics Corp.`s business and other risks set forth in Synbiotics Corp.`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corp.`s judgment as of the date of the release. Synbiotics Corp. disclaims, however, any intent or obligation to update these forward-looking statements.

Witness(R) is a registered trademark of Synbiotics Corp. VetScan(R) is a registered trademark of Abaxis Inc.


M.E. hat die Aktie großes Potential, wobei mein Kursziel für die nächsten sechs Monate bei $ 0,50 liegt.

Schaut Euch das Teil mal an!

[kosto1929]

OTC - Abzocke hoch 10

[Inkmarker]

#2

Wieso?

[Inkmarker]

In den letzten Handelstagen hat ein kleiner Aufwärtstrend eingesetzt.

Unter recht geringen Umsätzen geht es Tag für Tag knapp 10% an der OTC bergauf.

Also von mir aus kann es so weitergehen.

[Inkmarker]

Und es geht langsam weiter aufwärts!

Aktuell stehen wir bei $ 0,27.

Noch ist Zeit zum Einstieg. Wer Glück hat, kann ein paar Stücke in Ffm abstauben, wo der Kurs derzeit bei € 0,19 steht.

[haribo]

Ich hoffe das Sie aus den Pinks wieder rauskommen.

[Klatsch]

San Diego, Kalifornien: August 16, 2004 - Synbiotics Corporation (SBIO) verkündete heute, daß es ein Reineinkommen während des zweiten Viertels von 2004 von $357.000 oder von $0.01 pro den Anteil notierte, der mit einem Reineinkommen von $224.000 oder von $0.01 pro Anteil während des zweiten Viertels von 2003 verglichen wurde. Die Firma verkündete auch heute, daß sie einen Reinverlust für die sechs Monate beendet Juni 30, 2004 ($138.000) oder ($0.01) pro des Anteiles notierte, der mit Reineinkommen von $1.623.000 oder von $0.08 pro Anteil verglichen wurde ($0.04 auf einer verdünnten Grundlage) während der vorherigen Jahrperiode. Das zweite Viertel von 2004 Resultaten schließen eine Rechtsstreitregelung Gutschrift von $850.000 oder von $0.04 pro Anteil ein ($0.02 pro Anteil auf einer verdünnten Grundlage). Die Resultate für die sechs Monate beendeten Juni 30, 2003, schlossen eine Rechtsstreitregelung Gutschrift ein, die zur Rechtsstreitregelung 2004, von $515.000 oder von $0.03 pro Anteil ohne Bezug ist ($0.01 pro Anteil auf einer verdünnten Grundlage). Die Resultate für das zweite Viertel von 2004 und die sechs Monate beendet Juni 30, 2004 schließen auch bedeutende Anwaltskosten ein. Einkommen Synbiotics` waren $4.728.000 während des zweiten Viertels von 2004, eine Abnahme von 3% von $4.871.000 während der vorherigen Jahrperiode. Einkommen für die sechs Monate beendet Juni 30, 2004 waren $9.906.000 ein Abnahme von 10% von $11.021.000 für die sechs Monate beendet Juni 30, 2003. Die Abnahme an beiden Perioden liegt an der zusätzlichen Konkurrenz im Hunde- heartworm Diagnosemarkt hauptsächlich, Versatz durch Zunahmen der Abgabeeinkommen, resultierend aus den Rechtsstreitregelungen 2004 und 2003. Paul Heu, Synbiotics` Der Präsident und funktionierender Hauptoffizier, besagt, "Our Abweichung vom letzten Jahr im Einkommen für die erste Hälfte waren unserem Kampf im Markt und im Gerichtssaal gegen Agen biomedizinisches begrenztes zuzuschreibend. Uns werden der Patentrechtsstreit sind hinter uns gefallen; er erlaubt uns, auf das Verstärken unseres Geschäfts durch stärkere Marketing-Tätigkeiten und durch eine wiederbelebte Entwicklung Rohrleitung zu konzentrieren. Angestellte Synbiotics` werden eingeweiht mehr als überhaupt dem Wachsen unseres Geschäfts entsprechend unserem Anblick und Mission." Synbiotics Corporation entwickelt, stellt her und vermarktet Veterinärdiagnose, Instrumentenausrüstung und in Verbindung stehende Produkte für das Begleitertier, großes Tier und Geflügelmärkte weltweit. Hauptsitz gehabt in San Diego, stellt Kalifornien, Synbiotics her und verteilt seine Produkte durch seine Betriebe in San Diego, in Kalifornien und in Lyon, Frankreich. Zu Information über Synbiotics und seine Produkte, besichtigen Sie die Web site der Firma an www.synbiotics.com. Mit Ausnahme von historischen Angelegenheiten, die Ausgaben, die in diesem Pressekommuniquã© besprochen werden, Vorwärts-schauen Aussagen, die sind, die abhängig von den Gefahren und Ungewißheiten, die tatsächliche Resultate veranlassen konnten, sich von denen materiell zu unterscheiden, die in den Vorwärts-schauenden Aussagen, einschließlich die Notwendigkeit, der Firma umzustrukturieren vorweggenommen wurden, die gereift wurde, aber unbezahltes Darlehen von Kreditinstituten, Konkurrenz von den größeren Firmen, Vertrauen auf aus dritter Quelle Herstellern und Verteilern, mögliche Technologieverbesserungen durch andere, die Jahreszeitlichkeit der Hauptteile des Company`s Geschäfts und andere Gefahren festgelegt Synbiotics Corporation`s in den Archivierungen mit der Sicherheiten und Austausch-Kommission, besonders Form 10-K für das Jahr beendet Dezember 31, 2003. Diese Vorwärts-schauenden Aussagen stellen Synbiotics Corporation`s Urteil ab dem Datum der Freigabe dar. Synbiotics Corporation dementiert, jedoch, jede mögliche Absicht oder Verpflichtung, diese Vorwärts-schauenden Aussagen zu aktualisieren.

[kurttilly]

Heute bei SYNBIO:

Starke Umsätze und steigender Kurs in USA !!!!

Kommt SYNBIO wieder zum Laufen ????

mfg


kurttilly

[Klatsch]

natürlich werden die kommen. Ich verkaufe kein STück. Bin von der Fa. überzeugt.

[kurttilly]

Hallo Klatsch!

Auch ich hab mir überlegt, zu verkaufen; aber schau einer an .....


... bei großen Umsätzen 0,22 USD + 47%


... wir bleiben dabei !!!


mfg

kurttilly

[Klatsch]

Habe die wirklich günstigen Kurse genutzt um zu kaufen.
Der Kurs ist fast grundlos zu tief gegangen, und er wird steigen. Die Zahlen sind doch auch nicht so schlecht. Wir werden sehen........................

Auf gute Kurse!

[js200]

Synbiotics Corp. Reports Second Quarter Results

Monday , August 16, 2004 15:38 ET

SAN DIEGO, Aug 16, 2004 (BUSINESS WIRE) -- Synbiotics Corp. (Pink Sheets:SBIO) today announced that it recorded a net income for the second quarter of 2004 of $357,000 or $0.01 per share compared to a net income of $224,000 or $0.01 per share for the second quarter of 2003. The company also announced today that it recorded a net loss for the six months ended June 30, 2004 of ($138,000) or ($0.01) per share compared to net income of $1,623,000 or $0.08 per share ($0.04 on a diluted basis) for the prior year period.

The second quarter of 2004 results include a litigation settlement credit of $850,000 or $0.04 per share ($0.02 per share on a diluted basis). The results for the six months ended June 30, 2003, included a litigation settlement credit, unrelated to the 2004 litigation settlement, of $515,000 or $0.03 per share ($0.01 per share on a diluted basis). The results for the second quarter of 2004 and the six months ended June 30, 2004 also include significant legal expenses.

Synbiotics` revenues were $4,728,000 for the second quarter of 2004, a decrease of 3% from $4,871,000 for the prior year period. Revenues for the six months ended June 30, 2004 were $9,906,000 a decrease of 10% from $11,021,000 for the six months ended June 30, 2003. The decrease in both periods is primarily due to additional competition in the canine heartworm diagnostic market, offset by increases in royalty revenues resulting from the litigation settlements in 2004 and 2003.

Paul Hays, Synbiotics` President and Chief Operating Officer, said, "Our deviation from last year in earnings for the first half was attributable to our fight in the market and in the courtroom against Agen Biomedical Limited. We are pleased the patent litigation is behind us; it allows us to focus on strengthening our business through stronger marketing activities and through a revitalized development pipeline. Synbiotics` employees are dedicated more than ever to growing our business according to our vision and mission."

Synbiotics Corp. develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, California, and Lyon, France. For information on Synbiotics and its products, visit the company`s Web site at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including the need to restructure the company`s matured but unpaid bank loan, competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the company`s business and other risks set forth in Synbiotics Corp.`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corp.`s judgment as of the date of the release. Synbiotics Corp. disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE: Synbiotics Corp.


CONTACT: Synbiotics Corp.
Paul R. Hays, President & COO
858-451-3771, ext. 1401
[e-mail]
or
Keith A. Butler, Vice President and CFO
858-451-3771, ext. 1413
[e-mail]

Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.



Copyright (C) 2004 Business Wire. All rights reserved.


-0-


KEYWORD: CALIFORNIA FRANCE INTERNATIONAL EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL
MEDICAL
MEDICAL
DEVICES
EARNINGS


STOCK SYMBOLS: [(sbio)]

[GlobalKonzept]

Synbiotics Corp. Reintroduces Witness FeLV

BW5785 AUG 24,2004 15:44 PACIFIC 18:44 EASTERN


( BW)(CA-SYNBIOTICS)(SBIO) Synbiotics Corp. Reintroduces Witness FeLV

Business Editors/Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--Aug. 24, 2004--Synbiotics Corp. (PinkSheets:SBIO) today announced that the USDA has approved theirWitness(R) FeLV antigen test kit. The kit rejoins Synbiotics´Witness(R) line of veterinary diagnostics that includes the Witness(R)HW canine heartworm antigen test and the Witness(R) Relaxin pregnancytest for dogs and cats.
Synbiotics has been a leader in feline leukemia virus diagnosticssince 1987 with ViraCHEK(R)/FeLV, Synbiotics´ feline leukemia virusELISA microwell test, as one of the premier FeLV diagnostics availabletoday. Witness(R) FeLV utilizes Rapid Immuno Migration (RIM(R))technology, similar to that found in home pregnancy test kits, tosimplify the testing procedure and eliminate the wash step required byELISA tests. Its small sample size -- only 0.05 ml of whole blood,plasma or serum -- makes it ideal for testing young kittens oruncooperative adults.
"Witness(R) tests, thanks to their accuracy, speed and simplicity,have achieved a significant level of success both in the U.S. andinternational markets," according to Paul Hays, President and COO ofSynbiotics. "We are pleased that our new relationship with a localcompany, with a proven record of innovation in the development andmanufacture of high performance immunoassays, has enabled us to resumethe supply of Witness(R) FeLV. Our FeLV product will soon be followedby Witness(R) CPV canine parvovirus fecal antigen test kit."
Witness(R) FeLV is available as a 10-test kit from Synbiotics´Distributors.
Synbiotics Corp. develops, manufactures and markets veterinarydiagnostics, instrumentation and related products for the companionanimal, large animal and poultry markets worldwide. Headquartered inSan Diego, Synbiotics manufactures and distributes its productsthrough its operations in San Diego and Lyon, France. For informationon Synbiotics and its products, visit the company´s Web site atwww.synbiotics.com.

With the exception of historical matters, the issues discussed inthis press release are forward-looking statements that are subject tothe risks and uncertainties that could cause actual results to differmaterially from those anticipated in the forward-looking statements,including the need to restructure the company´s matured but unpaidbank loan, competition from larger companies, reliance on third-partymanufacturers and distributors, possible technology improvements byothers, the seasonality of major portions of the company´s businessand other risks set forth in Synbiotics Corp.´s filings with theSecurities and Exchange Commission, particularly Form 10-K for theyear ended December 31, 2003. These forward-looking statementsrepresent Synbiotics Corp.´s judgment as of the date of the release.Synbiotics Corp. disclaims, however, any intent or obligation toupdate these forward-looking statements.

Das war nur der Anfang ! Ihr werdet sehn die kommen noch ganz doll - Einziger Makel sie werden derzeit in den Pinksheets notiert wegen verspaeteter Abgabe eines Finanzberichts! Moeglicherweise war das sogar beabsichtigt um den Kurs zu druecken und sich billig einzudecken.

Gruss

Global Konzept

[Inkmarker]

Nachdem die Quartalszahlen zuletzt ja nicht so toll waren, und die Aktie entsprechend abgestraft wurde.

Ging es nach der Meldung von gestern mit dem Kurs ja wieder Berg auf.

Ich finde, dass die Nachrichtenlage insgesamt nicht schlecht ist, so m.E. in absehbarer Zeit mit weiteren Kurssteigerungen zu rechnen ist.

Grüße Inkmarker

[fussballspieler]

@all

mal sehen wie der kurs heute verläuft. geht die aufwärtsbewegung weiter oder war es nur ein strohfeuer???

gruß
fussballspieler

[Inkmarker]

Bis jetzt bleibt der Kurs konstant bei $ 0,23.

Ich hoffe mal, dass es sich nur um einen kurzen Zwischenstop auf der Reise nach Norden handelt.




Grüße Inkmarker

[Eicher0815]

Sers.
Weiß jemand wann die wieder aus den Pinksheets rauskommen?

[Werterherr]

Na,

wenn ein Herzwurm- und auch noch Schwangerschaftstest für Hunde sowie Katzen genehmigt wurde, dann kann es ja nur bergauf gehen, die 0,30 $ sollte in den nächsten Wochen fallen.

[zigu_88]

Kennt jemand die Gründe für den Anstieg der letzten Tage? Habe die Aktie nicht mehr verfolgt seit sie in den Pink Sheets sind.

[Inkmarker]

Die Gründe liegen wohl zweifelsohne in der Meldung, die im Posting # 13 wiedergegeben wurde.

[GlobalKonzept]

9-Sep-2004

Entry Material Agreement, Sale of Equity, Financial Statements and Exhibits



Item 1.01. Entry into a Material Definitive Agreement.
On September 2, 2004, we entered into a Series C Purchase Agreement (the "Series C Agreement") with Redwood Holdings, LLC, Paul Hays and Fintan and Janice Molloy. Under the Series C Agreement, simultaneously with, and contingent upon, the restructuring of our bank debt, we will sell to the above named parties a total of 250 shares of newly-issued shares of unregistered Series C Preferred Stock of Synbiotics Corporation for consideration totaling $250,000 in cash. Redwood Holdings, LLC and Mr. Hays will each receive 100 shares, and Mr. and Mrs. Molloy will receive 50 shares. Redwood Holdings, LLC owns 4.0125% of Redwood West Coast, LLC, which owns 100% of the 2,800 shares of our Series C Preferred Stock currently outstanding. Thomas A. Donelan and Christopher P. Hendy, two of the three members of our board of directors, each own 24.9% of Redwood Holdings, LLC. Mr. Hays is our President and Chief Operating Officer, and is also a member of our board of directors. (See Item 3.02.)





Item 3.02. Unregistered Sales of Equity Securities.
On September 2, 2004, we entered into a Series C Purchase Agreement (the "Series C Agreement") with Redwood Holdings, LLC, Paul Hays and Fintan and Janice Molloy. Under the Series C Agreement, simultaneously with, and contingent upon, the restructuring of our bank debt, we will sell to the above named parties a total of 250 shares of newly-issued shares of unregistered Series C Preferred Stock (the "Series C Stock") of Synbiotics Corporation for consideration totaling $250,000 in cash. Redwood Holdings, LLC and Mr. Hays will each receive 100 shares, and Mr. and Mrs. Molloy will receive 50 shares. Each share of Series C Stock is convertible into 7,785 unregistered shares of our common stock (subject to anti-dilution adjustments). These securities are exempt from registration as the transaction is a Section 4(2) private offering, involving no underwriters.

On September 2, 2004, we declared a dividend on the Series C Stock, in the form of common stock with a value totaling $105,000, for dividends accrued and payable as of July 31, 2004. Redwood West Coast, LLC, the holder of the Series C Stock, as permitted by the Certificate of Determination of the Series C Stock, had elected to receive a dividend in the form of shares of our common stock in lieu of overdue cash dividends. As a result, 444,915 unregistered shares of our common stock were issued to Redwood West Cost LLC`s distributees on September 7, 2004. This issuance of unregistered equity securities does not require an exemption from registration as it does not constitute a "sale" of securities; however, in the event that an exemption would be required, the exemption would be a Section 4(2) private offering, involving no underwriters.





Item 9.01. Financial Statements and Exhibits.
a) Financial statements of businesses acquired

b) Pro forma financial information

c) Exhibits

10.97 Series C Purchase Agreement among the Registrant and Redwood Holdings, LLC, Paul Hays and Fintan and Janice Molloy, dated September 2, 2004.


Bald gehts los - Leute.

Gruss

GlobalKonzept

[Boersenkrieger]

un nu ?

[MarkV]

@ GlobalKonzept
Kannste das mal erläutern?
Was sagen uns diese Mitteilungen und was soll wann warum losgehn?

[MarkV]

Hey guys,

Im Januar/Februar wurde in einem anderen Thread über einen fälligen 5Mio. Kredit diskutiert. Der Fälligkeitstermin verstrich niemand wußte, was nun aus dieser Geschichte geworden ist. Alle gingen davon aus, daß die Sache geklärt sei, zumal man auch von den Banken nichts hörte.
Heute kommt endlich !!!!! die folgende Meldung; und siehe da, das Thema war alles andere als " vom Tisch" . Es war die ganze Zeit am köcheln. Kein Wunder, daß der Kurs der Aktie nicht aus dem Quark kam.

Hier die Meldung:

Press Release Source: Synbiotics Corporation

Synbiotics Corporation Announces Restructuring of Debt
Monday September 27, 1:01 pm ET


SAN DIEGO--(BUSINESS WIRE)--Sept. 27, 2004--Synbiotics Corporation (Pink Sheets:SBIO - News) today announced that it amended its credit agreement with Comerica Bank (" Comerica" ). The outstanding principal balance of the bank debt immediately prior to the amendment was \$4,472,000, all of which was due and payable. Under the amendment, Synbiotics issued an amended promissory note to Comerica in the amount of \$599,000, and Comerica sold the remaining principal of \$3,873,000 to Remington Capital, LLC (" Remington" ). Synbiotics simultaneously issued an amended promissory note to Remington in the amount of \$3,873,000.

" We had been unable to repay our earlier credit agreement loan since it matured on January 25, 2004. Our board of directors, management and employees are extremely pleased with this amended credit arrangement," said Paul Hays, President & COO of Synbiotics Corporation. " This not only remedies our default and relieves one of our greatest risks, it also puts the company on a realistic cash flow course as we seek to grow our business while servicing the debt."

The amended Comerica note bears interest at the rate of prime plus 2%, and is payable in monthly installments, from October 1, 2004 to August 1, 2007, of \$9,000 plus accrued interest (except the payments due on September 1, 2005 and 2006 are in the amount of \$151,000 plus accrued interest). The Remington note, which is subordinate to the Comerica note, bears interest at the fixed rate of 7.75%, and is payable in blended monthly installments of principal and interest, from September 25, 2004 to August 25, 2014, of \$46,485. Both the Comerica note and the Remington note are secured by substantially all of Synbiotics` assets.

Pursuant to the amendment, Synbiotics issued to both Comerica and Remington warrants to purchase 250,000 shares of unregistered Synbiotics common stock at an exercise price of \$0.17 per share. The warrants are exercisable at any time through September 1, 2010.

Synbiotics also announced that it entered into a Series C Purchase Agreement with Redwood Holdings, LLC, Paul Hays and Fintan and Janice Molloy. Under the agreement, simultaneously with the closing under the amendment of the credit agreement, Synbiotics sold to the above named parties a total of 250 shares of newly-issued shares of unregistered Series C Preferred Stock for \$250,000 in cash. Redwood Holdings, LLC and Mr. Hays each received 100 shares at the September 23, 2004 closing, and Mr. and Mrs. Molloy received 50 shares at the September 23, 2004 closing. Each share of Series C Stock is convertible at any time into 7,785 unregistered shares of our common stock (subject to anti-dilution adjustments).

Remington is indirectly owned 100% by Jerry L. Ruyan, Thomas A. Donelan and Christopher P. Hendy (collectively " Redwood" ). Redwood also owns 94% of the remaining 2,800 shares of the Synbiotics Series C Preferred Stock currently outstanding and is Synbiotics` controlling shareholder. Mr. Donelan and Mr. Hendy, two of the three members of Synbiotics` board of directors, each own 24.9% of Redwood Holdings, LLC. Mr. Hays is Synbiotics` President and Chief Operating Officer, and is also a member of Synbiotics` board of directors.

Quelle: http://biz.yahoo.com/bw/040927/275866_1.html

Mal sehen wie nun die Reaktionen sind. Ich muß gestehen, ich weiß nicht genau wie ich die Meldung werten soll. Es ist schon sehr erschreckend wenn man liest:
We had been unable to repay our earlier credit agreement loan since it matured on January 25, 2004
Das zeugt nicht gerade von solidem Finanzmanagement.

Andererseits ist nun vielleicht eine stabile Basis geschaffen die die finanzielle Situation von SBIO wieder kalkulierbar und somit für Investoren interessant macht. Der folgende Satz macht da Hoffnung:
This not only remedies our default and relieves one of our greatest risks, it also puts the company on a realistic cash flow course as we seek to grow our business while servicing the debt."

Was meint Ihr zu dieser Meldung?
Für mich bedeutet es zumindest, daß ich nicht mehr grübeln werde, ob ich investiert bleibe. Ich glaube es wird jetzt auf keinen Fall mehr abwärts gehen.

Gruß,

[MarkV]

ohhhhhhh,

andere Anleger scheinen das etwas anders zu sehen als ich.
Der Kurs geht erst mal runter

[champYio]

ja weil einer mal für ganze 610 € 5000 aktien verkauft
hat.

wenn der umsatz insbesondere in usa nicht stimmt,
passiert hier auch leider
nicht viel

[GlobalKonzept]

Die Umsätze die zur Zeit zustande kommen sind reine Zufallsereignisse und die Kurs damit auch. Last Euch nicht davon irritieren. Jetzt ist die Zeit zum Einsammeln und liegenlassen.
Diese Firma macht immerhin ca. 20 Mill. Dollar Umsatz, das heist pro Aktie etwa 1 Dollar. Gut in der Vergangenheit sind Fehler gemacht worden, aber ich denke das Managment hat gelernt und ist dementsprechend vorsichtig. Die Produkte braucht der Markt und es ist ein wachsender Markt. Sobald sich der Turn-around abzeichnet wird die Aktie anspringen und mehr als 1 Dollar wäre dann bei steigenden Umsätzen leicht machbar. Wenn Ihr die Umsätze der letzten 3 Monate zusammenrechnet, dann waren das nicht mal 5% der gesammten Aktien, daß heißt 95 % der Aktien sind in festen Händen und die wissen genau warum.

Gruss

GlobalKonzept

[steinuel]

jepp, stimme zu, bin zwar mit 40% im minus, bleibe aber auch an board. wird schon...

[Inkmarker]

Heute mal endlich wieder ein schönes plus. Wir stehen mal wieder bei $ 0,22.

Geht es jetzt mal endlich wieder nachhaltiger in Richtung Norden?

[Werterherr]

Dem stimme ich zu. Die Bewegungen dieser Aktie sind derzeit kaum nachzuvollziehen, die langfristigen Aussichten immernoch gut. Auf jeden Fall halten.

[steinuel]

weiß jemand, wann die quartalsergebnisse präsentiert werden? ich versteh das problem dieser aktie einfach nicht. einer der führenden hersteller weltweit. wer erklärt mir das problem???

[MarkV]

@steinuel

führender Hersteller weltweit???
schau mal hier nach http://finance.yahoo.com/q/co?s=SBIO.PK, vielleicht siehst Du das dann anders.

92 Mitarbeiter,
Konkurrent ist z.B. Sanofy-Aventis

Gruß,
MarkV

[fussballspieler]

@all

Synbiotics Corporation Reports Third Quarter Results
11/16/04


SAN DIEGO, Nov 16, 2004 (BUSINESS WIRE) --
Synbiotics Corporation (Pink Sheets:SBIO) today announced that it recorded a net loss for the third quarter of 2004 of ($164,000) or ($0.02) per share compared to a net loss of ($252,000) or ($0.01) per share for the third quarter of 2003. The company also announced today t
hat it recorded a net loss for the nine months ended September 30, 2004, of ($390,000) or ($0.03) per share compared to net income of $1,459,000 or $0.07 per share ($0.03 on a diluted basis) for the prior year period.

The results for the nine months ended September 30, 2004, include a litigation settlement gain of $850,000 or $0.04 per share, and the results for the nine months ended September 30, 2003, included a litigation settlement gain, unrelated to the 2004 litigation settlement, of $515,000 or $0.03 per share ($0.01 per share on a diluted basis). The results for the nine months ended September 30, 2004, also include significant legal expenses.

Synbiotics` revenues were $4,333,000 for the third quarter of 2004, an increase of 4% over $4,169,000 for the prior year period. The increase is primarily due to the re-launch of Synbiotics` Witness(R) feline leukemia virus product and increased sales of instrument products, as well as a 9% increase in foreign currency exchange rates. Revenues for the nine months ended September 30, 2004, were $14,239,000, a decrease of 6% from $15,190,000 for the nine months ended September 30, 2003. The decrease is primarily due to additional competition in the canine heartworm diagnostic market from Agen Biomedical Ltd., offset by increases in royalty revenues resulting from the litigation settlements in 2004 and 2003 and also offset by a 10% increase in foreign currency exchange rates.

Paul Hays, Synbiotics` President and Chief Operating Officer, said, "Though the last eighteen months has had its challenges brought by the termination by Agen Biomedical, Ltd. of our Witness(R) supply in April of 2003, the subsequent patent and contractual litigation with Agen and the resulting difficult market conditions for heartworm diagnostics, we are looking forward. Re-establishing our Witness(R) brand products supply, settling the litigation and refinancing our bank debt have been important milestones indicating we have turned the corner. Our employees are actively working on several projects to expand our product line and increase our market penetration to reduce our reliance on heartworm diagnostic tests and create value for our customers while increasing shareholder value."

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company`s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE: Synbiotics Corporation

Synbiotics Corporation Paul R. Hays, President & COO, 858-451-3771 x1401 [e-mail] Keith A. Butler, Vice President and CFO 858-451-3771 x1413 [e-mail]

Copyright (C) 2004 Business Wire. All rights reserved.



Gruß
fussballspieler

[MarkV]

Scheußlich

[Klatsch]

Es ist hier ja sehr ruhig geworden....aber wie lange noch???
Da muß doch endlich mal was positives kommen, oder nicht??

[Inkmarker]

# 35

Das kann unter Umständen noch etwas dauern. Solange SBIO weiter in den Pk`s rumhängt, glaube ich nicht, dass es richtig losgeht.

Ich bin auch reichlich investiert, und bleibe dies auch. Die Geduld wird sich auszahlen. Man sollte bei weiter fallenden Kursen sukzessive nachkaufen, auch wenn dies in D`land nur noch in München möglich ist.

Auf jeden Fall sollte man Ruhe bewahren.


Grüße Inkmarker

[Klatsch]

Danke für deine Antwort. Habe heute alleine den Umsatz in München gemacht. Nutze auch die Möglichkeit nach zu kaufen.

Alles wird gut....hoffentlich...

Gruß

[Klatsch]

Februar 2005: Synbiotics verkündet die USDA Zustimmung ihres Zeuge ® CPV Hunde- parvovirus Antigen-Testinstallationssatzes. Der Installationssatz bringt Linie ® Zeuge Synbiotics` der Veterinärdiagnose wieder zusammen, die den Zeuge ® HW Hunde- heartworm Antigentest, Zeuge ® FeLV und den Zeuge ® Relaxin Schwangerschafttest für Hunde und Katzen einschließt. Synbiotics ist ein Führer in der Hunde- parvovirus Diagnose seit 1996 gewesen. Ihr Zeuge ® CPV Installationssatz bringt sich VERSICHERN ®/Parvo, Test parvovirus ELISA Synbiotics`, als einer der Diagnose des Premiers CPV wieder zusammen, die heute vorhanden ist. Zeugen Sie ® CPV verwendet die schnelle Immunmigration (KANTE ®) Technologie, die der ähnlich ist, die in den Hauptschwangerschafttestinstallationssätzen gefunden wird, um das Testverfahren zu vereinfachen und den Wäscheschritt zu beseitigen, der durch ELISA Tests erfordert wird. Im Installationssatz worden geschlossen Dacron ®-gespitzte Putzlappen für einfache Beispielansammlung ein. "zeugen Sie ® Tests, dank ihre Genauigkeit, Geschwindigkeit und Einfachheit, haben ein bedeutendes Niveau des Erfolges in den VEREINIGTEN STAATEN und in den Weltmärkten," nach Ansicht des Paul Heus, des Präsidenten und CEOS von Synbiotics erzielt. "wir sind erfreut, daß unser neues Verhältnis zu einer lokalen Firma, mit einer nachgewiesenen Aufzeichnung der Innovation in der Entwicklung und in der Herstellung von hohe Leistung immunoassays, uns ermöglicht hat, das Versorgungsmaterial von Zeuge ® CPV wieder aufzunehmen." Zeuge ® CPV ist in 5 und im 10-Test Installationssatz von den Verteilern Synbiotics` vorhanden © 2004 - Synbiotics Corporation. Alle Rechte vorbehalten.

Endlich mal was neues!!! Jetzt noch gute Zahlen, und dann..

[fussballspieler]

#38
wo hast du denn die info her??
kannst du vielleicht es mit eigenen worten beschreiben, was die info bedeutet??

gruß und vielen dank
fussballspieler

[Klatsch]

Auf der Internetseite von SBIO. Habe ich im Internet übersetzen lassen. Kannst dir ja den Originaltext mal anschauen und selbst übersetzen. Mein Englisch ist nicht gut genug.

Bis dann

[Klatsch]

San Diego, California: March 1, 2005 — Synbiotics Corporation (SBIO) today announced that Paul R. Hays, its President and Chief Operating Officer, has been appointed by the Board of Directors as Chief Executive Officer. Mr. Hays, who has been Synbiotics’ President and Chief Operating Officer since December 2002, has executed the responsibilities of Chief Executive Officer since that time as Synbiotics has not officially had a Chief Executive Officer.

“While Mr. Hays’ functional responsibilities have not changed,” said Thomas A. Donelan, Chairman of Synbiotics’ Board of Directors, “the Board of Directors has decided that the strong leadership qualities exhibited by Mr. Hays since joining the company warrant his formal recognition as Chief Executive Officer.”

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company’s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2003. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.

* * *





CONTACT: Keith A. Butler
Vice President and CFO
858-451-3771 x1413
[e-mail]

[Klatsch]

03/11/2005 - Synbiotics Corporation launches FLU DETECT™ Antigen Capture Test Strips

March 16, 2005- Synbiotics Corporation, the preferred resource for animal owners and professionals dedicated to the health and well-being of animals is pleased to announce the launch of FLU DETECT™ Antigen Capture Test Strip Kit which was uniquely design for veterinary use. The product, launched at VIV Asia, Bangkok, Thailand, detects all 15 H sub-types of Type A Flu. The product can be used farm side or in the laboratory for the detection of Type A Flu including H5N1, with higher sensitivity and specificity than similar products most of which have been developed for human use.

The FLU DETECT™ Antigen Capture Test Strip Kit is an in vitro rapid assay for the surveillance of Avian Influenza Virus. This test utilizes immunochromatographic technology. A positive test result appears within 15 minutes.

Bird flu has caused severe economic losses to the Southeast Asia poultry industry. This technology helps farmers, veterinarians, public health workers and government officials implement proper control measures, manage disease rapidly, and ultimately reduce the economic loss associated with this disease.

SYNBIOTICS Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. For more information on SYNBIOTICS Corporation and its products, visit the company website at www.synbiotics.com.

Contact :
Louis N. Vernon
Area Manager Asia
Tel : [phone] (ext 1101)
Email: [e-mail]

[Klatsch]

03/11/2005 - Synbiotics Corporation Introduces breakthrough in Porcine CircoVirus type 2 (PCV2) detection with two ELISAs for serum and/or feces antigen and antibody detection in swine in Asia

March 16, 2005- Synbiotics Corporation, the preferred resource for animal owners and professionals dedicated to the health and well-being of animals is pleased to announce the launching of the first commercially available test kits for Porcine Circovirus type 2 (PCV2). The two new ELISA test kits are:
- SERELISA® PCV2 Ab Mono Blocking for use on serum and feces samples and,
- SERELISA® PCV2 Ag Capture for use on feces samples.
Porcine CircoVirus type 2 (PCV2) is the causative agent in young swine of Postweaning Multisystemic Wasting Syndrome (PMWS), and thought to be part of the Porcine Respiratory Disease Complex (PRDC). However, subclinical infection with PCV2 is commonly found in production units.

These two new tests detect antibodies in serum or feces and antigen in feces. Internal as well as field trials have demonstrated and confirmed the performances of these innovative ELISAs as sensitive and specific diagnostic tests. Samples are processed through user friendly protocols, including rapid or alternative overnight incubation. SERELISA® PCV2 Ab Mono Blocking and SERELISA® PCV2 Ag Capture can be performed in less than three hours and are useful diagnostic tools that will aid swine industry professionals in deciding on intervention strategies to control PCV2.

SYNBIOTICS Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. For more information on SYNBIOTICS Corporation and its products, visit the company website at www.synbiotics.com.
Contact :
Louis N. Vernon
Area Manager Asia
Tel : [phone] (ext 1101)
Email: [e-mail]

[Inkmarker]

Wenn die Aktie aus den Pk`s rauskommt, kann es wieder schnell bis auf $ 1,00 hoch gehen.

Allerdings muss man Geduld haben!

[Inkmarker]

NEWS von SBIO!

Die Aktie geht ab!

Momentan ein Plus von 60% und im Hoch waren wir auch schon mit 80% im Posiiven.

Wenn die Aktie nur nicht in den Pk`s gelistet wäre, wäre das Potential noch um ein Vielfaches größer.

Hier mal die Meldung als link:

http://www.synbiotics.fr/english/pdf/VIV-Flu%20Detect%20Pres…

[GoldenStock]

Zeit wirds ja das Synbiotics endlich mal wieder Richtung
Norden geht......
Bin blos gespannt wann sie endlich aus den Pink-Sheets
raus sind ?!?
Allerdings sehe ich die jetztigen Kurse eher als
Schnäppchen.
Sollten Sie bald wieder im OTC handelbar sein, und ein paar gute News wieder kommen, sind auch meiner Meinung nach, Kurse von 1 Euro wieder drin.
GoldenStock

[Inkmarker]

Sehe ich, wie schon unten gepostet, genauso.

M.E. hat die Aktie extrem viel Potential. Der springende Punkt ist aber die Notiz in den Pk´s.

Bis es SBIO schafft da raus zu kommen, heißt es bei mir sukezive einsammeln. Bin schon seit über einem Jahr dabei und kaufe selbst immer wieder nach.

Bei SBIO kann man mit ruhigen Gewissen abwarten.

[Inkmarker]

Übrigens: Lt. der SBIO-homepage ist SBIO im Mai 2005 auch auf einer Messe in Deutschland mit dabei.

[Klatsch]

Moin, Moin!
Ich habe eine Meldung im Internet mal übersetzen lassen, weil ich finde diese Meldung ist der Hammer.
Sbio hat einen Teststreifen eingeführt, der innerhalb von 15 Minuten bei Tieren die gefährliche Vogelgrippe feststellen kann. Hier der Text ( wie gesagt im Internet übersezt). Was meint Ihr dazu???






03/15/2005 - Synbiotics Corporation stößt GRIPPE ERMITTELN aus? Antigen-Sicherung Test-Streifen März 16, 2005- Synbiotics Corporation, das bevorzugte Hilfsmittel für Tierinhaber und die Fachleute, die der Gesundheit und dem Wohl der Tiere eingeweiht werden, freut sich, um die Produkteinführung der GRIPPE zu verkünden ERMITTELN? Antigen-Sicherung Test-Streifen-Installationssatz, der einzigartig für Veterinärgebrauch bestimmt war. Das Produkt, ausgestoßen bei VIV Asien, Bangkok, Thailand, ermittelt alle 15 H Formationsglieder der Art eine Grippe. Das Produkt kann benutzte Bauernhofseite oder im Labor für die Abfragung der Art sein eine Grippe einschließlich H5N1, mit höherer Empfindlichkeit und Besonderheit als ähnliche Produkte; die meisten, denen sich für menschlichen Gebrauch entwickelt haben. Die GRIPPE ERMITTELN? Antigen-Sicherung Test-Streifen-Installationssatz ist eine schnelle in-vitroprobe für die Überwachung des Vogelgrippe-Virus. Dieser Test verwendet immunochromatographic Technologie. Ein positives Testergebnis erscheint innerhalb 15 Minuten. Vogelgrippe hat strenge ökonomische Verluste zur Südostasien Geflügelindustrie verursacht. Diese Technologie hilft Landwirten, Tierärzten, Arbeitern des öffentlichen Gesundheitswesens und Regierungsbeamten, korrekte Kontrollmaßnahmen schnell einzuführen, handhat Krankheit und verringert schließlich den ökonomischen Verlust, der mit dieser Krankheit verbunden ist. SYNBIOTICS Corporation vermarktet dieses in bestimmten asiatischen und europäischen Ländern sofort und stellt das Produkt global zur Verfügung, sobald die jeweiligen Regierung Zustimmungen das Einschließen in den Vereinigten Staaten nach USDA licensure bewilligt werden. SYNBIOTICS Corporation entwickelt, stellt her und vermarktet Veterinärdiagnose, Instrumentenausrüstung und in Verbindung stehende Produkte für das Begleitertier, großes Tier und Geflügelmärkte weltweit. Zu mehr Information über SYNBIOTICS Corporation und seine Produkte, besichtigen Sie die Firmaweb site am www.synbiotics.com. ________ Kontakt: Louis N. Vernon Area Manager-Asien Telefon: (Ext. 1101) email [phone]: [e-mail] Brenda Glidewell Globales Technisches Direktor-Geflügel Telefon: (Ext. 1803) email [phone]: [e-mail]

[Inkmarker]

Deswegen ist die Aktie ja auch langfristig so interessant!

Kurse von über $ 1 sind leicht möglich, wenn die Vogelgrippe wieder ausbricht, und vorallem wenn SBIO endlich aus den Pk`s rauskommt.

Fantasie besteht auch bzgl. event. Aufträge aus Asien.

Allerdings sollte man Geduld mitbringen, denn solange SBIO in den Pk´s ist, wird es m.E. eohl keinen anhaltenden Kursanstieg geben. Würde mich allerdings freuen, wenn ich mich irre.

[GoldenStock]

Meridian Bioscience Expands Presence in Veterinary Market and Announces Agreement with Synbiotics Corporation

CINCINNATI--(BUSINESS WIRE)--March 16, 2005--Meridian Bioscience, Inc., (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Viral Antigens, Inc. (VAI), has entered into a Distribution Agreement with Synbiotics Corporation for the distribution of VAI`s veterinary products through Synbiotics` global sales, marketing, and distribution channels. Synbiotics develops, manufactures, and markets veterinary diagnostic products for the animal health market and is seeking to broaden its product portfolio. Synbiotics will immediately begin marketing VAI`s line of Pseudorabies Virus Antibody (PRV) test kits. VAI will continue to supply PRV test kits directly to Japan.

Pseudorabies Virus (PRV) is a contagious swine disease that causes reproductive problems, including abortion, stillbirths and death losses in breeding and finishing hogs. PRV has been one of the most costly of all swine diseases to the nation`s pork producers. At its peak in the 1990`s, the cost to pork producers alone was estimated to be $30 million annually represented in vaccination, testing, and animal loss costs. Over the past decade, a national control and eradication program for PRV was implemented to eliminate the presence of PRV in the swine population. Today, vaccination, testing, and good disease management practices are utilized to control the impact of PRV. PRV testing has been a significant factor in the eradication of Pseudorabies in more than 20,000 farms in the U.S. Continued surveillance testing in the U.S. and efforts to eradicate PRV outside the U.S. continue to be important initiatives in controlling PRV disease.

VAI and Synbiotics will also explore additional veterinary diagnostic product opportunities within the $700 million global animal health diagnostic market.

Richard L. Eberly, Executive Vice President and General Manager, Meridian Life Science, stated, "We are pleased to have developed a close partnership with Synbiotics and believe that our combined expertise will provide a broader portfolio of high quality products for our global animal health customers."

Paul R. Hays, Chief Executive Officer of Synbiotics Corporation, stated, "We are excited that the collaboration of the VAI and Synbiotics` teams will provide our mutual customers with new and exciting products in the future and strengthen our relationships with them. Providing innovative products that yield value to the customer is the key to success and having a company like VAI collaborate with us will make new products come to fruition faster."

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, and respiratory infections. Meridian diagnostic products are used outside of the human body and require little or no special equipment. The Company`s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents and specialty biologicals along with proteins and other biologicals used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices and diagnostics manufacturers in more than 60 countries around the world. The Company`s shares are traded through Nasdaq`s National Market, symbol VIVO. Meridian`s website address is www.meridianbioscience.com.

CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, 513-271-3700

SOURCE: Meridian Bioscience, Inc.

[GoldenStock]

Übringends.........

Merdidian hat ne Marktkap. von 250.000.000 Million Dollar.
Synbiotics hat ne Marktkap von 3.000.000 Million Dollar.

Ist wohl nur ne Frage der Zeit, wann Synbiotics
sich auf den Weg macht............

Grüßle
GoldenStock

[Inkmarker]

Ganz aktuell:

NTV-Text: Junge an Vogelgrippe in Vietnam erkrankt.

[fussballspieler]

vielleicht geht ja doch noch was bei der aktie.

kleinvieh macht auch mal misst

14:14:16 0,150 5.200

Kursdaten 29.03.2005 München
Kurs:
14:14:16
0,150
+111,27%
+0,079

gruß
fussballspieler

[GoldenStock]

03/28/2005 - Synbiotics Corporation Reports Year End Results
San Diego, California: March 28, 2005 — Synbiotics Corporation (SBIO) today announced its results for the year ended December 31, 2004. Net loss for the year was ($647,000) or ($0.04) per share compared to net income of $1,287,000 or $0.06 per share ($0.03 on a diluted basis) for 2003.

Synbiotics’ revenues were $19,219,000 for 2004 as compared to $19,211,000 for 2003. The 2004 results include significant legal expenses related to patent litigation which was settled in 2004, as well as disappointing performance from Synbiotics’ subsidiary, Synbiotics Europe SAS.

The auditors’ opinion on the 2004 financial statements, as in 2003, contained a going concern explanatory paragraph.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company’s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2004. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.

* * *

Paul R. Hays
President & CEO
858-451-3771 x1401
[e-mail]

Keith A. Butler
Vice President and CFO
858-451-3771 x1413
[e-mail]

[GoldenStock]

03/28/2005 - Synbiotics Corporation Reports Year End Results
San Diego, California: March 28, 2005 — Synbiotics Corporation (SBIO) today announced its results for the year ended December 31, 2004. Net loss for the year was ($647,000) or ($0.04) per share compared to net income of $1,287,000 or $0.06 per share ($0.03 on a diluted basis) for 2003.

Synbiotics’ revenues were $19,219,000 for 2004 as compared to $19,211,000 for 2003. The 2004 results include significant legal expenses related to patent litigation which was settled in 2004, as well as disappointing performance from Synbiotics’ subsidiary, Synbiotics Europe SAS.

The auditors’ opinion on the 2004 financial statements, as in 2003, contained a going concern explanatory paragraph.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company’s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2004. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.

* * *

Paul R. Hays
President & CEO
858-451-3771 x1401
[e-mail]

Keith A. Butler
Vice President and CFO
858-451-3771 x1413
[e-mail]

[Inkmarker]

Jetzt heißt es wieder einsammeln. Kurs an der OTC am Ende bei $ 0,07.

[Inkmarker]

Schaut Euch mal den Jahresabschluss 2004 an!

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=000…

Ist die Firma wirklich nur $ 1.480.780 wert (21.154.000 austehende Aktien/ Kurs: $ 0,07)?

[Inkmarker]

Synbiotics Corporation to Seek Shareholder Approval to Go Private



SAN DIEGO--(BUSINESS WIRE)--April 19, 2005--Synbiotics Corporation (Pink Sheets:SBIO) today announced that it will seek shareholder approval for Synbiotics to "go private." Specifically, Synbiotics is proposing a 1-for-2,000 reverse split of its common stock, with a payment in lieu of issuing fractional shares, followed by a 2,000-for-1 forward split of its common stock. The cash payment in lieu of fractional shares will be at the rate of $0.13 per pre-reverse split share traceable to the fractional shares.

The purpose of the proposal is to reduce the number of Synbiotics` shareholders of record to below 300. This, in turn, will enable Synbiotics under the applicable legal standards to elect to deregister its securities under the Securities Exchange Act of 1934 (the "1934 Act"), thereby "going private." Synbiotics would deregister as soon as possible, in order to (i) eliminate the costs associated with preparing and filing documents under the 1934 Act with the U.S. Securities and Exchange Commission; (ii) eliminate or reduce the costs and other burdens associated with being a 1934 Act registrant, including the costs of complying with Section 404 of the Sarbanes-Oxley Act of 2002 as to internal control over financial reporting; (iii) avoid the requirement of regular mandatory disclosure of financial information and management analyses, to the public but also to our competitors and commercial counterparties, even when such disclosure would be adverse to a Synbiotics objective; (iv) reduce the costs of administering shareholder accounts and responding to shareholder requests; (v) provide liquidity to shareholders holding less than 2,000 pre-reverse split shares of common stock; and (vi) provide greater flexibility in the management and governance of Synbiotics. The cost savings associated with "going private" would be, Synbiotics believes, a minimum of $245,000 in the first full year alone.

In order to finance the cash payment in lieu of fractional shares, Synbiotics has entered into an agreement to sell 180 newly issued and unregistered shares of Series C preferred stock to Redwood Holdings, LLC for $180,000 cash. Redwood Holdings, LLC is an affiliate of Synbiotics` controlling shareholder, Redwood West Coast, LLC, and its directors Thomas A. Donelan and Christopher P. Hendy. Any such sale of Series C preferred stock is contingent upon the shareholder approval of the proposed transaction. This equity investment to maintain cash levels is required by Synbiotics` lender Comerica Bank as a condition to its waiver of Synbiotics` covenant not to repurchase common stock.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company`s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the seasonality of major portions of the Company`s business and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2004. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.


CONTACT: Synbiotics Corporation
Paul R. Hays
President & CEO
858-451-3771 x1401
[e-mail]
or
Keith A. Butler
Vice President and CFO
858-451-3771 x1413
[e-mail]

SOURCE: Synbiotics Corporation

[Inkmarker]

Für mich entscheidend:

"... Specifically, Synbiotics is proposing a 1-for-2,000 reverse split of its common stock, with a payment in lieu of issuing fractional shares, followed by a 2,000-for-1 forward split of its common stock. The cash payment in lieu of fractional shares will be at the rate of $0.13 per pre-reverse split share traceable to the fractional shares. ..."

Babelfish sagt dazu:

"...Spezifisch schlägt Synbiotics einen umgekehrten Aktiensplit 1-for-2,000 seiner Stammaktien, mit einer Zahlung anstatt der Ausgabe der Bruchanteile vor, gefolgt von einem 2,000-for-1, das vorwärts von seinen Stammaktien aufgespaltet wird. Die Barzahlung anstatt der Bruchanteile ist mit der Rate von $0.13 pro den Vorrückaufgeteilten Anteil, der zu den Bruchanteilen traceable ist. ..."


Also wenn ich das Ganze richtig verstehe, läuft es im Ergebnis darauf hinaus, dass wir $ 0,13 pro Aktie erhalten, oder?

[Inkmarker]

Wenn ich mir die Bilanz vom 31.12.2004 anschaue, komme ich mir da irgendwie verschauckelt vor.

Ich hoffe mal, dass das letze Wort da noch nicht gesprochen ist, und wie noch ein paar Cents mehr erhalten.

[Inkmarker]

Filing das nach Börsenschluss veröffentlicht wurde (lt. Pk):

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549




--------------------------------------------------------------------------------



FORM 8-K




--------------------------------------------------------------------------------



CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported): April 19, 2005




--------------------------------------------------------------------------------



SYNBIOTICS CORPORATION

(Exact name of registrant as specified in its charter)




--------------------------------------------------------------------------------



Commission file number 0-11303




California 95-3737816
(State or other jurisdiction

of incorporation )
(I.R.S. Employer

Identification No.)


11011 Via Frontera

San Diego, California
92127
(Address of principal executive offices) (Zip Code)



Registrant’s telephone number, including area code: [phone]




--------------------------------------------------------------------------------



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Item 1.01. Entry into a Material Definitive Agreement.



On April 19, 2005, we entered into a Series C Purchase Agreement (the “Series C Agreement”) with Redwood Holdings, LLC. Under the Series C Agreement, contingent upon the shareholder approval, and subsequent effectuation, of a reverse stock split, which is part of an intended “going private” transaction, we will sell to Redwood Holdings, LLC 180 shares of newly-issued shares of unregistered Series C preferred stock of Synbiotics Corporation for consideration totaling $180,000 in cash. Redwood Holdings, LLC and its affiliates currently are the beneficial owners of 56% of our common stock and 87% of our Series C preferred stock. (See Items 3.02 and 8.01.)



Item 3.02. Unregistered Sales of Equity Securities.



On April 19, 2005, we entered into a Series C Purchase Agreement (the “Series C Agreement”) with Redwood Holdings, LLC. Under the Series C Agreement, contingent upon the shareholder approval, and subsequent effectuation, of a reverse stock split, which is part of an intended “going private” transaction, we will sell to Redwood Holdings, LLC 180 shares of newly-issued shares of unregistered Series C preferred stock of Synbiotics Corporation for consideration totaling $180,000 in cash. Each share of Series C preferred stock is convertible at any time into 7,785 unregistered shares of our common stock (subject to anti-dilution adjustments). This transaction is intended to be a Section 4(2) private offering, involving no underwriters.



Item 8.01 Other Events.



On April 19, 2005, we issued a press release announcing that we will be seeking shareholder approval of a “going-private” transaction.



Item 9.01. Financial Statements and Exhibits.




a) Financial statements of businesses acquired

Not applicable.

b) Pro forma financial information

Not applicable.

c) Exhibits

10.106 Series C Purchase Agreement between the Registrant and Redwood Holdings, LLC, dated April 19, 2005.

99 Press release dated April 19, 2005, entitled “Synbiotics Corporation to Seek Shareholder Approval to Go Private.”



-1-



--------------------------------------------------------------------------------

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




SYNBIOTICS CORPORATION

Date: April 19, 2005
/s/ Keith A. Butler

--------------------------------------------------------------------------------

Keith A. Butler

Vice President - Finance and Chief Financial Officer




-2-

Exhibit 10.106



SERIES C PURCHASE AGREEMENT



This Series C Purchase Agreement is entered into as of April 19, 2005 between Redwood Holdings, LLC (the “Investor”) and Synbiotics Corporation (“Synbiotics”).



1. At a Closing to occur immediately upon the effectuation of a 1-for-2,000 reverse stock split of Synbiotics’ common stock approved by Synbiotics’ shareholders, Synbiotics shall issue and sell to the Investor, and the Investor shall purchase from Synbiotics, 180 newly-issued shares of unregistered Series C preferred stock of Synbiotics for $1,000 per share in cash.



2. Such shareholder approval of, and subsequent effectuation with the California Secretary of State of, the 1-for-2,000 reverse stock split of Synbiotics’ common stock is a condition precedent to the Closing.



3. The Investor represents to Synbiotics that it is acquiring the Series C preferred stock, and would acquire the underlying common stock, for its own account for investment and not with a view to distribution. Synbiotics has no obligation to register such securities with the SEC or any state.



4. The Investor has had full opportunity to read all of Synbiotics’ SEC filings on EDGAR.



5. This Series C Purchase Agreement constitutes the entire agreement among the parties with regard to the subject matter hereof, and supersedes all prior and contemporaneous agreements, commitments and discussions with regard to such subject matter. This Series C Purchase Agreement can be amended only in writing. . . .

[Knollebauer]

Meldung war ab 2:17 pm bekannt, die paar noch shareholder konnten sich wohl auch noch nicht so recht entscheiden:

Time & Sales
Price Size Time
0.095 2000 15:38:42
0.09 5000 14:30:30
0.09 5000 14:26:29
0.09 5000 14:22:36
0.09 5000 14:22:12
0.095 5000 14:22:08
0.095 5000 14:22:06
0.105 1600 14:21:49
0.10 5000 14:19:19
0.10 5000 14:19:13
0.094 1000 14:19:08
0.10 5000 14:19:08
0.10 5000 14:18:52
0.10 5000 14:18:50
0.095 10000 14:18:50
0.10 5000 14:18:49
0.08 52700 14:18:39
0.09 5000 14:18:18
0.09 10000 14:18:01
0.09 10000 14:17:54
0.08 13000 14:17:36
0.09 10000 14:17:31
0.10 5000 14:17:29
0.10 5000 14:17:28
0.09 5000 14:17:20
0.08 5000 14:17:11
0.08 5000 14:16:22
0.08 1999 14:15:53
0.07 10700 14:15:24
0.07 245 14:07:27

@ink: was ist eigentlich außer der Handelbarkeit der Unterschied zw. common stocks und serie c aktien ?

Gruß
Knolle
PS hab meine Bank mal angemailt wegen dem filing
stell die evtl. Antwort hier rein

[Inkmarker]

@Knollebauer!

Was konkret der Unterschied ist, kann ich Dir auch nicht genau sagen.

Mir ist auch noch nicht klar, ob sich der reverse-split nur auf die Aktien bezieht, die an den Investor ausgegeben werden, oder ob alle Aktien davon betroffen sind.

Falls Deine e-mail beantwortet wird, kannst Du sie ja mal reinstellen.


Grüße Inkmarker

[Inkmarker]

Synbiotics Corporation Reports First Quarter Results



SAN DIEGO--(BUSINESS WIRE)--May 13, 2005--Synbiotics Corporation (Pink Sheets:SBIO) today announced its financial results for the quarter ended March 31, 2005. Net income for the quarter was $60,000 or $0.00 per share compared to a net loss of ($495,000) or ($0.034) per share for the first quarter of 2004.

Synbiotics` revenues were $5,072,000 for the first quarter of 2005 as compared to $5,178,000 for the first quarter of 2004.

The first quarter of 2004 results include significant legal expenses related to patent litigation which was settled in 2004.

Synbiotics Corporation develops, manufactures and markets veterinary diagnostics, instrumentation and related products for the companion animal, large animal and poultry markets worldwide. Headquartered in San Diego, California, Synbiotics manufactures and distributes its products through its operations in San Diego, CA, and Lyon, France. For information on Synbiotics and its products, visit the Company`s website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to the risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, the effects of Synbiotics Corporation`s announced intention to "go private" and other risks set forth in Synbiotics Corporation`s filings with the Securities and Exchange Commission, particularly Form 10-K for the year ended December 31, 2004 and Form 10-Q for the quarter ended March 31, 2005. These forward-looking statements represent Synbiotics Corporation`s judgment as of the date of the release. Synbiotics Corporation disclaims, however, any intent or obligation to update these forward-looking statements.


CONTACT: Synbiotics Corporation
Paul R. Hays, President & CEO
858-451-3771 x1401
[e-mail]
Keith A. Butler, Vice President and CFO
858-451-3771 x1413
[e-mail]

SOURCE: Synbiotics Corporation

Sieht doch gar nicht mal so schlecht aus, wie der Kurs es erwarten läßt.

Und auf einmal werden auch pünktlich die Quartalszahlen geliefert.

Ich bin weiter optimistisch, dass ein Abfindungsangebot in Höhe von $ 0,13 auch für die übrigen Aktien kommt.


Zur Erinnerung: Es erfolgt ein Re-split 1:2000, wobei die nicht durch 2000-teilbare Aktienzahl mit $ 0,13 abgefunden wird, und danach wird 2000:1 zurück gesplitet.

Also wird die Aktienanzahl im Ergebnis verringert.

[Inkmarker]

Hier ein link auf das komplete Filing:

http://www.pinksheets.com/quote/print_filings.jsp?url=%2Fred…


Sollte es SBIO nicht gelingen, die Anzahl der Aktionäre auf unter 300 zu drücken, muss wohl ein Abfindungsangebot hinsichtlich aller ausstehenden Aktien ergehen, um das "go private" durchzuziehen.

[GlobalKonzept]

Form 10-K/A for SYNBIOTICS CORP


--------------------------------------------------------------------------------

15-Jun-2005

Annual Report



Item 7. Management`s Discussion and Analysis of Financial Condition and Results of Operations
The information contained in this Management`s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this Annual Report on Form 10-K contains both historical financial information and forward-looking statements. Forward-looking statements are characterized by words such as



--------------------------------------------------------------------------------

Table of Contents
"intend", "plan", "believe", "will", "would", etc. Historical financial information may not be indicative of future financial performance. In fact, future financial performance may be materially different than the historical financial information presented herein. Moreover, the forward-looking statements about future business or future results of operations are subject to significant uncertainties and risks, including those detailed under the caption "Certain Risk Factors", which could cause actual future results to differ materially from what is suggested by the forward-looking information.

Overview

We are still working to recover from the effects of our cash crisis in 2002. Our auditors` report on our 2004 financial statements contains a going-concern explanatory paragraph-a statement that there is substantial doubt about our ability to continue as a going concern. Our total revenues and net sales have been declining annually since 2000, although they were essentially flat in 2004 from 2003. We believe that our operations have stabilized and that, with continued attention to steady and careful execution of our turnaround business plan, we can increase shareholder value.

Our main challenge in 2005 will be to resolve our unsecured contractual obligations of $1,000,000 due in July 2005 and $1,500,000 due in July 2006, both to the same unrelated third party. We cannot afford to make these payments as scheduled. If we miss the July 2005 payment, the entire obligation will be accelerated and will begin bearing interest at 10.5%.

In September 2004, we successfully resolved a similar situation, where we were unable to pay at maturity the remaining $4,804,000 principal amount of our loan from Comerica Bank. The resolution involved extension and amendment of the loan terms and the sale by Comerica of most of the loan to a company affiliated with Redwood West Coast, LLC, our majority shareholder.

The profitability of our canine heartworm diagnostic products has diminished due to competition from new entrants to the in-clinic canine heartworm diagnostics market, Heska and Agen. We believe their products infringed our U.S. patent in this area, and we separately sued them for patent infringement. Although we incurred significant litigation costs, the final settlements of these cases in 2003 and 2004 did not include barring their products from the market. Agen`s distributor appears to be following a price-cutting strategy, so this new competition is adversely affecting both our market share and our average selling price. In any event, our U.S. patent in this area expires in December 2005, and after then we would be unable to prevent any further additional competitors from entering this market.

We believe our results in 2005 and thereafter will benefit if we can avoid the heavy patent litigation expense we experienced in 2002, 2003 and, particularly, 2004. We currently are not involved in any litigation.

Our management and board of directors are beginning to explore a possible transaction that would result in our ceasing to be subject to SEC filing and reporting requirements. This possible transaction is a reverse stock split in which shareholders who do not hold a minimum number of shares of our common stock would have their shares converted into cash. Such a transaction would also result in a slight increase in the equity ownership of our shareholders whose shares are not converted into cash.

We have been monitoring the costs of operating as a publicly reporting company to determine whether, in our judgment, the direct and indirect costs outweigh the benefits to us and our shareholders. We incur significant costs associated with being a publicly traded company. Among other things, these costs include legal fees and audit fees (including fees for quarterly reviews performed by our auditors). In 2004, we began incurring the direct and indirect costs associated with Sarbanes-Oxley Act Section 404 compliance, and these will add significantly to our costs. The expenses associated with implementing the additional processes and procedures necessary for Section 404 compliance, which was originally to take effect for our fiscal year 2005 but has now been delayed by the SEC until our fiscal year 2006, and the required attestation of those controls have been



--------------------------------------------------------------------------------

Table of Contents
estimated to be equal to the entire cost of the fiscal 2004 year-end audit. Moreover, Section 404 compliance will inevitably result in a diversion of management time and attention from other duties.

We have not reached any conclusion about whether the costs of being a publicly traded SEC reporting company outweigh the benefits, but as noted above we are evaluating a possible transaction the effect of which would be that we would no longer remain an SEC reporting company. Any such transaction would be designed to result in our having less than 300 stockholders of record, making us eligible to cease making SEC filings, such as annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statement disclosures, as well as our not having to comply with Section 404. While there would be a one-time cost to this transaction, which would be subject to shareholder approval, we believe that the decrease in ongoing direct costs would be approximately $150,000 per year.

If we decide to do a transaction as described above, public trading in our common stock, which is currently traded over-the-counter, would effectively become impossible after we opted out of our SEC filing obligations, due to the lack of publicly available information about us such as financial statements.

Results of Operations

Year Ended December 31, 2004 Compared to Year Ended December 31, 2003

Our net sales for 2004 decreased by $59,000 or less than 1% from 2003. The decrease reflects a decrease in our diagnostic product sales of $613,000 offset by an increase in our instrument product sales of $554,000, and also reflects a 10% increase in foreign currency exchange rates which affects the consolidation of SBIO-E and itself added $638,000 to our 2004 revenues. Sales of our diagnostic products decreased primarily due to additional competition in the canine heartworm diagnostic market from Agen Biomedical Ltd. ("Agen"), as well as disappointing performance at SBIO-E. Agen`s in-clinic canine heartworm diagnostic product is similar to our Witness canine heartworm diagnostic test kit. Our instrument product sales increased primarily due to increased placements of our SCA 2000™ blood coagulation timing instrument and the resulting sales of the related consumables, as well as increases in the average selling prices of the consumables.

Agen is currently distributing its products in the U.S. through Vedco, a co-operative buying group. Several of the member-owners of this buying group also distribute our canine heartworm and other products, but have decided to promote Agen`s canine heartworm product instead of ours. Additionally, Agen`s distributors marketed the canine heartworm product with a price which is significantly less than previously established prices in this market. As a result, we have been forced to compete on price and our average selling price for our Witness canine heartworm product during 2004 was 16% less than that during 2003. We do not believe that this price erosion will be easily reversed, especially after our U.S. canine heartworm detection patent expires in late 2005.

In April 2003, Agen terminated its supply agreement with us. Agen had been our contract manufacturer for certain of our Witness in-clinic diagnostic products including canine heartworm, feline leukemia, feline heartworm and canine parvovirus, using key biological components which we manufacture at our facilities and had provided to Agen. We then identified a U.S.-based alternate contract manufacturer of the same Witness products previously manufactured for us by Agen. We licensed the alternate-source Witness canine heartworm product with the USDA, and we began selling this product in January 2004. We licensed the alternate-source Witness feline leukemia product with the USDA, and began selling this product in August 2004. Our alternate-source canine parvovirus product was licensed by the USDA, and we began selling this product, in February 2005. In addition to the material impact during 2004, we also believe that our results of operations and financial condition could be materially adversely affected in 2005 and beyond if we are unable to fully succeed in reintroducing the alternate-source products into the market.

In December 2004, one of our distributor customers placed an order totaling $546,000, which was shipped and invoiced in December 2004. The order represented approximately 50% of the customer`s prior twelve months purchases. We believe that due to the size of the order, the customer will not be placing any significant



--------------------------------------------------------------------------------

Table of Contents
orders with us during the first quarter of 2005. Because the heartworm selling season straddles December and the first part of the next year, our year-to-year periodic results often vary as a result of such timing differences.

We recognize revenue from product sales when title and risk of loss transfers to our customer, which is generally upon shipment. Amounts we charge to our customers for shipping and handling are included in our net sales. We provide promotional discounts and rebates to certain of our distributors. Based upon the structure of these rebate programs and our past history, we are able to accurately estimate the amount of rebates at the time of sale. These rebates are recorded as a reduction of our net sales. We recognize license fee revenue ratably over the license term when we have further performance obligations to our licensee. In the event that we have no further performance obligations to our licensee, we recognize license fee revenue upon receipt.

Our cost of sales as a percentage of our net sales was 48% during 2004 as compared to 49% during 2003. The decrease is due to improved margins on our Witness canine heartworm diagnostic and feline leukemia products due to a change in contract manufacturers (offset by decreased selling prices), and on our SCA 2000™ consumables due to increased selling prices. A significant portion of our manufacturing costs are fixed.

Among our major products, our DiroCHEKcanine heartworm diagnostic products and our poultry products are manufactured at our facilities, whereas our WITNESS in-clinic canine heartworm, feline leukemia, and canine parvovirus diagnostic products and our SCA 2000 ™ instrument products are manufactured by third parties. We manufacture the key biological materials contained in our WITNESScanine heartworm, feline leukemia and canine parvovirus diagnostic products. In addition to affecting our gross margins, outsourcing of manufacturing renders us relatively more dependent on the third-party manufacturers. Agen, the previous contract manufacturer of certain of our Witness products, ceased to supply us with those products In April 2003. We then identified a U.S.-based alternate contract manufacturer of the same Witness products previously contract manufactured for us by Agen, and the cost of these products to us is lower than the cost of those contract manufactured for us by Agen. However, we lost substantial sales during the hiatus between the two contract manufacturers. In 2004 we incurred costs to re-license the in-clinic feline leukemia and canine parvovirus diagnostic products with the USDA, and we incurred costs in 2003 to re-license the in-clinic canine heartworm diagnostic product with the USDA.

Our research and development expenses increased by $309,000 or 26% during 2004 as compared to 2003. The increase is a result of a $103,000 increase in research and development expenses contracted by us from a third party, and increase of $68,000 in laboratory supplies, and $56,000 directly reflecting an increase in foreign currency exchange rates over 2003 of 10%. The increase in the foreign currency exchange rates affects the consolidation of SBIO-E. Our research and development expenses as a percentage of our net sales were 8% and 6% during 2004 and 2003, respectively.

Our selling and marketing expenses did not change significantly during 2004 as compared to 2003. Our selling and marketing expenses as a percentage of our net sales were 22% during 2004 and 2003.

Our general and administrative expenses increased $2,139,000 or 61% during 2004 as compared to 2003. The increase is primarily due to $1,314,000 of legal expenses associated with our lawsuit with Agen. We hope to minimize legal expenses in 2005, and we are not currently involved in any litigation. In addition, an extra $158,000 of our 2004 general and administrative expenses were simply due to an increase in foreign currency exchange rates over 2003 of 10%. The increase in the foreign currency exchange rates affects the consolidation of SBIO-E. Our general and administrative expenses as a percentage of our net sales were 30% and 18% during 2004 and 2003, respectively.

In December 2004, the Financial Accounting Standards Board ("FASB") issued FASB Statement No. 123R, "Share-Based Payments" ("FAS 123R"). FAS 123R is a revision of FASB Statement No. 123, "Accounting for Stock-Based Compensation", and supersedes APB Opinion No. 25, "Accounting for Stock Issued to Employees" and its related implementation guidance.



--------------------------------------------------------------------------------

Table of Contents
FAS 123R requires that the cost of all awards of equity instruments made to employees in exchange for employment services be recorded at fair value on the grant date, and the cost be charged to expense as the award vests. The determination of fair value is based upon option-pricing models (for example, Black-Scholes) adjusted for characteristics unique to the equity instrument.

We will be required to charge to expense the fair value of employee stock options which vest on or after July 1, 2005, and we expect to record compensation expense related to unvested employee stock options outstanding as of December 31, 2004, as follows: 2005-$33,000; 2006-$67,000; 2007-$46,000; 2008-$9,000.

In September 2003, we filed a lawsuit against Agen alleging that Agen infringed a patent owned by us relating to canine heartworm diagnostic technology. In June 2004, we entered into a settlement agreement with Agen which resolved all outstanding claims in the lawsuit. As part of the agreement, each party licensed certain intellectual property rights from the other party, including Agen licensing from us the patent relating to the canine heartworm diagnostic technology, and we received $425,000 in June 2004, and we will receive $425,000 in June 2005. As a result, we recorded a one-time credit to operating expenses totaling $850,000 during 2004. In addition, we agreed that we will continue to supply certain proprietary biologicals to Agen at specified prices, and we will receive a percentage of Agen`s sales of Agen products containing the supplied biologicals. The Agen products compete directly with similar products of ours in the marketplace.

In November 1998, we filed a lawsuit against Heska Corporation alleging that Heska infringed a patent owned by us relating to heartworm diagnostic technology. In March 2003, we entered into settlement and license agreements with Heska which resolved all outstanding claims in the lawsuit. As part of those agreements, each party has licensed certain intellectual property rights from the other party, including Heska licensing from us the patent relating to the heartworm diagnostic technology. In addition, we received $250,000 in April 2003, and we are receiving $265,000 in 24 monthly installments of $11,000 beginning in January 2004. As a result, we recorded a one-time credit to operating expenses totaling $515,000 during 2003. In addition, Heska agreed to make royalty payments to us on its sales of licensed canine heartworm diagnostic products beginning April 2003, until our patent expires in December 2005.

As a result of these settlement agreements, our royalty income during 2004 increased by $67,000 or 17% as compared to 2003. Any future royalty income will, of course, depend on the other companies` net sales, which tend to be at the expense of our own product sales; also, depressed pricing in the market will tend to reduce the other companies` net sales and thus reduce our future royalty income.

Our net interest expense decreased by $46,000 or 9% during 2004 as compared to 2003. The decrease is due to decreases in the outstanding principal balance of our bank debt, and due to the restructuring of our bank debt in September 2004.

We recognized a benefit from income taxes of $60,000 during 2004 as compared to a benefit from income taxes of $2,000 during 2003. The change is due primarily to an $84,000 deferred foreign tax benefit related to SBIO-E in 2004, offset by current foreign income tax expense related to SBIO-E during 2004 and minimum state income taxes in 2004.

A review of our business, in light of the market, reveals that our food animal diagnostics are not meeting their relative geographic sales potentials. Food animal diagnostics measure the health of herds or flocks and provide information for the economic management of herds or flocks. We currently manufacture all our poultry products at our San Diego, California facility and the majority of our livestock products at our Lyon, France facility. Both lines perform better in their local markets. Our intent is to better internationalize those portfolios. We are also developing, both internally and through in-licensing arrangements, new food animal diagnostic products that would expand and enhance our existing product line. These growth opportunities will necessitate additional expenses in research and development as well as improved marketing to effectively target this market



--------------------------------------------------------------------------------

Table of Contents
if the development projects come to fruition successfully. In March 2005, we effected a two-person reduction in force at SBIO-E, in part as a result of this review. The reduction in force related to senior management positions. Due to severance costs associated with this reduction in force, the impact on our 2005 results of operations will be negligible. The savings from the reduction in force will be more readily evident in our 2006 results of operations.

Year Ended December 31, 2003 Compared to Year Ended December 31, 2002

Our net sales for 2003 decreased by $2,557,000 or 12% from 2002. The decrease reflects a decrease in our diagnostic product sales of $2,858,000 offset by an increase in our instrument product sales of $301,000. Sales of our diagnostic products decreased due to the termination by Agen of our supply agreement under which Agen supplied us with certain of our Witness diagnostic products, as discussed below, leaving us with no inventory of these products for over half the year. Our instrument product sales increased primarily due to increased placements of our SCA 2000™ blood coagulation timing instrument, and the resulting sales of the related consumables.

In April 2003, we were notified by Agen that Agen was terminating its supply agreement with us due to late payment of invoices for test kits. Agen had been the contract manufacturer for certain of our Witness in-clinic diagnostic products including canine heartworm, feline leukemia, feline heartworm and canine parvovirus, using key biological components which we manufacture at our facilities and had provided to Agen. These Witness products represented $4,345,000 and $8,069,000 of our net sales during 2003 and 2002, respectively.

We identified a U.S.-based alternate contract manufacturer of the same Witness products previously manufactured for us by Agen and began the process of licensing the alternate-source Witness products with the USDA.

Agen introduced into the U.S. market in October 2003 a canine heartworm diagnostic product which is essentially identical to our Witness canine heartworm diagnostic test kit, including biological components which incorporate our patented technology. In September 2003, we filed a patent infringement lawsuit against Agen claiming that Agen has willfully infringed our U.S. Patent No. 4,789,631 pertaining to heartworm detection technology. In addition to seeking damages, we asked for an injunction against Agen, preventing Agen from importing, selling or offering for sale their canine heartworm diagnostic test kit in the United States. The lawsuit was ultimately settled in June 2004.

Our cost of sales as a percentage of our net sales was 49% during 2003 and 2002. The preservation of margin despite reduced sales was heartening, because a significant portion of our internal manufacturing costs are fixed. Among our major products, our DiroCHEK canine heartworm diagnostic products and our poultry products are manufactured at our facilities, whereas our WITNESS in-clinic canine heartworm, feline leukemia, and canine parvovirus diagnostic products and our SCA 2000 ™ instrument products are manufactured by third parties. We manufacture the key biological materials contained in our WITNESS canine heartworm, feline leukemia and canine parvovirus diagnostic products. In addition to affecting our gross margins, outsourcing of manufacturing renders us relatively more dependent on the third-party manufacturers. Agen, the previous contract manufacturer of certain of our Witness products, ceased to supply us with those products In April 2003. We identified a U.S.-based alternate contract manufacturer of the same Witness products previously contract manufactured for us by Agen, and the cost of these products to us is lower than the cost of those contract manufactured for us by Agen. In 2003 we also incurred costs to re-license these products with the USDA.

Our research and development expenses decreased by $203,000 or 15% during 2003 as compared to 2002. The decreases are a result of a cost reduction program that was implemented at the end of the third quarter of 2002, offset by costs incurred 2003 related to the re-launching of our Witness canine heartworm product. Our research and development expenses as a percentage of our net sales were 6% during 2003 and 2002.



--------------------------------------------------------------------------------

Table of Contents
Our selling and marketing expenses decreased $228,000 or 5% during 2003 as compared to 2002. The decreases are a result of a cost reduction program, including reductions in headcount, that were implemented at the end of the third quarter of 2002. Our selling and marketing expenses as a percentage of our net sales were 22% and 20% during 2003 and 2002, respectively.

Our general and administrative expenses decreased by $5,283,000 or 60% during 2003 as compared to 2002. The decrease during 2003 was primarily attributable to the non-recurrence of $3,682,000 of retention bonuses that became payable in the first quarter of 2002. The decrease was also attributable to a cost reduction program, including reductions in headcount, that was implemented at the end of the third quarter of 2002, and favorable effects of foreign currency exchange rates on our intercompany balances. 2002 expenses were also higher due to severance costs for three senior officers, including our former chief executive officer. Our general and administrative expenses as a percentage of our net sales were 19% and 41% during 2003 and 2002, respectively. Excluding the first quarter 2002 bonus expense our general and administrative expenses would have been $5,090,000 or 24% of our net sales during 2002.

In 2003 we incurred $421,000 of litigation expenses related to the Agen and Heska lawsuits. Our litigation expenses in 2002 were $161,000, all for the Heska lawsuit.

In November 1998, we filed a lawsuit against Heska Corporation alleging that Heska infringed our U.S. Patent No. 4,789,631 relating to heartworm diagnostic technology. In March 2003, we entered into settlement and license agreements with Heska which resolved all outstanding claims in the lawsuit. As part of those agreements, each party has licensed certain intellectual property rights from the other party, including Heska licensing from us the patent relating to the heartworm diagnostic technology. In addition, we received $250,000 in April 2003, we will receive $265,000 in 24 monthly installments of $11,000 beginning in January 2004. As a result, we recorded a one-time credit to operating expenses totaling $515,000 during 2003. We receive royalty payments on sales of licensed canine heartworm diagnostic products beginning April 2003. We recognized royalty income related to this license totaling $277,000 during 2003.

Our net interest expense decreased by $177,000 or 26% during 2003 as compared to 2002. The decrease was due to decreases in the prime rate, and to decreases in the outstanding principal balances of our bank debt.

We recognized a benefit from income taxes of $2,000 during 2003 as compared to a provision for income taxes of $7,000 during 2002. We are limited in the utilization of certain of our Federal and state net operating loss carryforwards. As a result of this limitation, $15,351,000 of our Federal net operating loss carryforwards, and $969,000 of our state net operating loss carryforwards, may expire before they can be utilized. In addition, California placed a moratorium on the utilization of net operating loss carryforwards for 2003.

In the first quarter of 2002, we adopted Statement of Financial Accounting Standards No. 142 ("FAS 142"), "Goodwill and Other Intangible Assets". In connection with the adoption of FAS 142, we performed a transitional goodwill impairment assessment. As a result of this impairment assessment, we recorded an impairment of $7,649,000, net of income tax benefit of $106,000, which is classified as a cumulative effect of a change in accounting principle in the first quarter of 2002. FAS 142 requires that we perform subsequent impairment assessments on an annual basis, or on an interim basis if events occur that may cause an impairment of our goodwill and other intangible assets. In 2002, as a result of the annual assessment based upon the market price of the our common stock on December 31, 2002, we recorded an additional impairment loss of $2,877,000. Based upon the market price of the Company`s common stock on December 31, 2003, there was no impairment loss resulting from the annual impairment assessment in 2003.



--------------------------------------------------------------------------------

Table of Contents

Financial Condition and Liquidity



The following table summarizes the future cash payments related to our
contractual obligations (other than trade payables) as of December 31, 2004
(amounts are in thousands):



Total 2005 2006 2007 2008 2009 Thereafter
------- ------- ------- ----- ----- ----- ------------
Long-term debt $ 4,381 $ 546 $ 542 $ 390 $ 343 $ 371 $ 2,189
Operating leases 4,833 956 766 524 414 414 1,759
Other long-term obligations 2,500 1,000 1,500

[GlobalKonzept]

Wenn man sich die Seite von

finance.yahoo.com/q/mh?s=SBIO.PK

anschaut, dann findet man dort die 4 Hauptinvestoren die zusammen fast 65 % der Anteile halten. Und alle haben noch in diesem Jahr zugekauft zu Kursen von 0,1285 Dollar je Aktie.

Diese Investoren wissen mehr! Synbiotics kriegen ihre Probleme in den Griff und dann geht der Zug ab.
Wenn Sie aus den Pinksheets raus sind dann kommt es zur Kursexplosion - 100 % ist da garnichts.

Noch ein Aspekt. Es sieht danach aus das in Zukunft der Dollar gegenüber dem EURO wieder stärker wird und wir zur Parität zurückkehren, zusätzlicher Hebel also.

Jetzt in Amerika investieren. Synbiotics kaufen !!! Derzeit absolute Einkaufskurse.

Leider muss man 2 Wochen warten bis man einen Posten durch Teilausführungen zusammen hat.

Gruss

GlobalKonzept

[Inkmarker]

Also für $ 0,07 kann man ohne Probleme kaufen in den USA!

Das die Hauptinvestoren groß zu $ 0,1285 eingestiegen sind macht natürlich Sinn.

SBIO plant ja einen "go private", d.h. sie wollen sich von der Börse zurückziehen. Dies geht allerdings nur, wenn die Anzahl der Aktionäre unter 300 sinkt. Deshalb soll ja auch zunächst ein Re-split 1:2000 stattfinden, und die nicht durch 2000 teilbaren Teilaktien zu $ 0,13 abfunden werden. Danach soll wieder ein Split 2000:1 erfolgen.

Man kann also verschiedene Spekulationen anstellen:

1. Man kauft 1.999 Aktien, und läßt sich diesen Betrag zu $ 0,13 abfinden, was immerhin einem Plus von fast 100% entspricht.

2. Man kauft eine größere Stückzahl und spekuliert darauf, dass nach einem erfolgreichen "go private" ein Abfindungsangebot auch für die übrigen Aktien kommt.

3. Der "go private" scheitert, weil es immer noch mehr als 300 Aktionäre gibt, und es kommt ein Übernahmeangebot für alle Aktien in Höhe $ 0,13.


Ich selbst spekuliere auf die letzte Variante, und habe mir schon etliche Stücke zugelegt.

Von mir aus kann die Aktie auch ruhig noch ein Stück fallen. Ich würde gern meine Aktienanzahl bei Kursen um $ 0,04 weiter ausbauen.

[GoldenStock]

Synbiotics - jetzt nachkaufen !!!!!!!!